Company: ATMCW
Filing Date: 2025-11-17
Form Type: DEFM14A
Source: 0001493152-25-023842
Chunk: 81

Company: ALPHATIME ACQUISITION CORP
Filing Date: 2025-11-17
Form: DEFM14A
Chunk 81
---
 owned subsidiary of TenX, Citius Pharmaceuticals, Inc., a Nevada corporation (“ Citius Pharma”), and Citius Oncology, Inc., a Delaware corporation and wholly owned subsidiary of Citius Pharma, to acquire Citius Oncology (the “ Citius Merger”). The combined company will own and operate the business of developing and commercializing LYMPHIRTM (denileukin diftitox), a late state oncology immunotherapy. TenX’s sponsor was 10XYZ Holding, L.P., a Delaware limited partnership (“ 10XYZ”). 10XYZ is controlled by its general partner, 10XYZ Management LLC, a Delaware limited liability company. Mr. Zhang is one of 10XYZ Management LLC’s two managing members. 10XYZ was formed for the purpose of acting as the sponsor in connection with TenX’s initial public offering, and the sponsor conducts no other business.

| 43 |

Pursuant to the third amended and restated memorandum and articles of association of TenX, TenX had until April 18, 2024 to consummate its business combination, provided however that TenX was able to subsequently extend the period of time to consummate a business combination up to seven (7) times for an additional one (1) month each time from April 18, 2024 to November 18, 2024, if requested by 10XYZ, subject to 10XYZ or its designee, depositing the lesser of (i) $66,667 or (ii) $0.03 per public share, for each month during the subsequent additional one (1) month extensions from April 18, 2024 to November 18, 2024, that is needed to complete an initial business combination.

Four (4) of the possible seven (7) time extensions were effected, on April 26, 2024, May 17, 2024, June 17, 2024, and July 17, 2024, respectively. On each such date, Citius Pharma deposited $66,667 into the trust account of TenX to extend the timeline to complete a business combination for an additional one (1) month period.

In connection with the TenX shareholder vote relating to the Citius Merger, holders of 4,297,828 TenX ordinary shares sold in TenX’s initial public offering properly exercised their rights to have such shares redeemed for a pro rata portion of the approximately $49,265,965.44 in the trust